GHK-Cu + Thymosin Alpha-1
The best-evidenced peptide here, and nobody agrees whether you can legally get it.
Thymosin alpha-1 has been through more than thirty clinical trials and is approved in over thirty-five countries. Pair it with GHK-Cu and you get tissue repair alongside immune support. Then you try to find out its legal status in the US and five sources give you five answers.
Ageing shows on the outside and happens on the inside.
Two payoffs, on different timescales. GHK-Cu is the visible one: firmer skin, softer fine lines, faded dark spots, better wound healing. It has the most human evidence of anything in the skin category and already sits in mainstream cosmetics, so this is the rare compound here whose main claim is well supported.
Thymosin alpha-1 is the one you would not see. It is used abroad for chronic infections and immune resilience, and it has more clinical trial evidence behind it than any other compound in this catalogue.
Thymosin alpha-1 covers what you cannot. The thymus gland shrinks steadily from adolescence onward, and with it the body's ability to train new immune cells. The pitch for this stack is resilience over appearance: keep the skin and keep the defences.
The two have no shared mechanism and no known interaction. They are pointed at different systems entirely, which makes this one of the cleaner pairings on the site and also means the case for combining them rests entirely on convenience.
More human evidence than anything else in this catalogue.
Almost every compound on this site is preclinical. This one is not.
The international manufacturer has not filed a New Drug Application with the FDA.[1] There is no rejection to point at, because there was never a submission. Everything about its American status flows from that gap.
Five sources. Five legal statuses. They cannot all hold.
We went looking for a straight answer on whether a US compounding pharmacy can legally prepare thymosin alpha-1 today. Here is what the sources say, in the order we found them.
13 days old
90 days old
110 days old
69 days old
173 days old
Two of these come from the same publication and point in opposite directions. Two describe the same February 2026 date as moving the compound in opposite directions. One says the date does not apply to it at all.
We are not going to pick one and call it the answer. Three things hold across all five, and they are worth having. Thymosin alpha-1 has no FDA approval for any use. It is approved as a medicine in more than thirty-five countries. Its US compounding status has been fought over since 2023, and every source we checked reports it differently.
If you need a real answer, ask a licensed compounding pharmacy. Expect it to vary by state. And if you are buying from a research chemical vendor, none of this applies to you anyway: that sits outside the framework entirely, whichever version turns out to be right.
A settlement, a committee, and nineteen peptides.
The parts every source agrees on are worth separating from the parts they fight over.
In September 2023 the FDA placed nineteen peptide substances into Category 2 of its interim policy on bulk substances for compounding. Category 2 means compounding pharmacies cannot legally use them. The list included BPC-157, TB-500, CJC-1295 and ipamorelin.[2]
A lawsuit followed, naming AOD-9604, CJC-1295, ipamorelin and thymosin alpha-1. In September 2024 the FDA settled and agreed to route several peptides through formal advisory committee review instead of holding them in Category 2 by its own decision.[2]
One distinction gets lost in most coverage. Removal from Category 2 is not permission to compound. It lifts the prohibition pending review. What the committee recommends afterwards is what decides the outcome, and turning a recommendation into a rule runs eight to twenty-four months when it happens at all.
GHK-Cu has good evidence for something people are not doing with it.
GHK-Cu has more human data behind it than almost anything else in the skin category. Nearly all of that data is topical: creams and serums applied to skin, measured on skin.
People in this stack are injecting it. The evidence does not cross over, and the mechanism argument for why it should has never been tested in a trial. Injected GHK-Cu is a different exposure at a different dose reaching different tissue than a serum on a face.
One handling detail carries over regardless. GHK-Cu is sensitive to light, and it is usually kept in its own vial instead of mixed with anything else.
No study has given both.
We found nothing testing GHK-Cu alongside thymosin alpha-1, in people or in animals. There is no known interaction between them and no shared pathway, which means no specific reason to expect trouble and no evidence of benefit from combining them either.
This is our own searching, not a systematic review. We will correct this page for anyone who can point to a trial.
What people ask about this pairing
Is thymosin alpha-1 legal in the US?
It has no FDA approval for any indication. Beyond that, sources disagree sharply. We checked five and got five different accounts of its compounding status, including two that describe the same February 2026 date as moving it in opposite directions. What holds across all of them: no US approval, approval as a medicine in more than 35 countries, and a compounding status contested since 2023. A licensed compounding pharmacy can tell you what applies in your state.
Why is it approved abroad but not in America?
The international manufacturer never filed a New Drug Application with the FDA. There is no rejection, because there was no submission. It is sold as Zadaxin in over 35 countries including Italy, China and the Philippines, mainly for chronic hepatitis B.
How strong is the evidence for thymosin alpha-1?
Stronger than anything else in this catalogue. More than 30 clinical trials covering over 11,000 human subjects, with randomised trials and meta-analyses in chronic hepatitis B, hepatitis C and severe sepsis. That evidence supports the indications it is approved for abroad. It does not automatically extend to general immune support in a healthy person, which is what most people in this stack are after.
Does the GHK-Cu skincare research apply if I inject it?
Not directly. GHK-Cu does have real human evidence for skin. Almost all of it comes from creams and serums put on the skin surface. Injecting it means a different dose reaching different tissue, and no trial has checked whether the cream results carry across.
Has anyone studied the two together?
No study we could find, in people or animals. They act on different systems with no shared pathway and no documented interaction, so there is no specific reason to expect a problem and no evidence of added benefit either. Compare against the other stacks.
Every reference carries how it was read, and where they disagree.
Sources 1 through 5 conflict with each other. All five are listed rather than resolved, because resolving them would mean picking one without grounds.
- 01Consumer health platform guide. Reports Category 2 status following the February 2026 reclassification, citing immunogenicity concerns. Also the source for the absence of an NDA submission.
- 02Clinic blog on the July 2026 advisory review. Source for the September 2023 Category 2 action, the lawsuit naming four peptides, the September 2024 settlement, and the December 2024 negative review.
- 03Clinic blog on thymosin alpha-1. Reports the 27 February 2026 HHS announcement moving roughly 14 of 19 peptides including this one back to Category 1.
- 04Peptide guide. Reports it was never in Category 2, was not part of the February 2026 announcement, and remained available through 503A pharmacies throughout.
- 05Vendor legal guide. Reports it is not on the 503A bulk substance list and cannot legally be compounded by any pharmacy. Also the source for international approvals in Italy and China and the absence of EMA, MHRA, TGA and Health Canada approval.
- 06Peptide Decoding vendor pricing data, 12 September 2026. Single-compound listings only.